Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 12,475 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cell Therapy Clear all
Completed Phase 1 Interventional

Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD)

NCT06638879
View directory record Official record
Conditions
Chronic Graft Versus Host Disease Oral
Interventions
Tacrolimus
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 40 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 30, 2026, 12:27 PM EDT
Suspended No phase listed Observational

Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma

NCT04657146
View directory record Official record
Conditions
Glioblastoma
Interventions
Biorepository
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 30, 2026, 12:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

NCT07227025
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Olomorasib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
New York, New York • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 12:27 PM EDT
Completed Phase 2 Interventional Results available

RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT04014790
View directory record Official record
Conditions
Graft Vs Host Disease, Graft-versus-host-disease, Acute-graft-versus-host Disease, Prevention of aGVHD
Interventions
RGI-2001, Standard of Care
Drug
Lead sponsor
Regimmune Corporation
Industry
Eligibility
18 Years to 64 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 30, 2026, 12:27 PM EDT
Completed Phase 2 Interventional

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

NCT03999710
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer, Nsclc, NSCLC Stage II, NSCLC, Stage III
Interventions
Radiation Therapy, Durvalumab
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 12:27 PM EDT
Terminated Phase 2 Interventional

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

NCT03913559
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Inotuzumab ozogamicin, Methotrexate, Hydrocortisone, Cytarabine, Diphenhydramine, Acetaminophen, Methylprednisolone
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
San Diego, California • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 30, 2026, 12:27 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

NCT00375674
View directory record Official record
Conditions
Kidney Neoplasms
Interventions
Sunitinib malate, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
12
States / cities
Los Angeles, California • Atlanta, Georgia • Marrero, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 30, 2026, 12:27 PM EDT
Completed Early Phase 1 Interventional

Raltegravir for HAM/TSP

NCT01867320
View directory record Official record
Conditions
HTLV-I Infection
Interventions
Raltegravir
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 30, 2026, 12:27 PM EDT
Completed Phase 1 Interventional

LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy

NCT04081259
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
LY3214996
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 30, 2026, 12:27 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT01557959
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cisplatin, pegfilgrastim, erlotinib hydrochloride, laboratory biomarker analysis, polymorphism analysis, pharmacogenomic studies, genetic linkage analysis, docetaxel
Drug · Biological · Other + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 30, 2026, 12:27 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
58
States / cities
Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 12:27 PM EDT
Terminated Phase 2 Interventional Results available

Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

NCT00618540
View directory record Official record
Conditions
Histiocytosis, Langerhans-cell
Interventions
alemtuzumab, fludarabine phosphate, melphalan, stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 30, 2026, 12:27 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer

NCT04095689
View directory record Official record
Conditions
Triple Negative Breast Cancer, Anthracycline-refractory TNBC
Interventions
Docetaxel, Pembrolizumab, IL-12 gene therapy
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 30, 2026, 12:27 PM EDT
Terminated Phase 1 Interventional

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

NCT00003613
View directory record Official record
Conditions
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
Interventions
O6-benzylguanine, carmustine, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2013 · Synced Oct 30, 2026, 12:27 PM EDT
Completed Phase 1 Interventional

Adoptive Transfer of Haploidentical NK Cells and N-803

NCT03899480
View directory record Official record
Conditions
Hiv, HIV Infections, Immune Deficiency
Interventions
Haploidentical Natural Killer (NK) Cells
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 30, 2026, 12:27 PM EDT
Completed Phase 2 Interventional

A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine

NCT00001688
View directory record Official record
Conditions
HIV Infection
Interventions
Ritonavir, Nevirapine, Stavudine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 12:27 PM EDT
Completed No phase listed Observational

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis

NCT02716103
View directory record Official record
Conditions
Amyloidosis
Interventions
blood collection, bone marrow collection
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 30, 2026, 12:27 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)

NCT02934503
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Pembrolizumab, Cisplatin, Carboplatin, Etoposide, Radiation therapy
Biological · Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 30, 2026, 12:27 PM EDT
Not yet recruiting Phase 1 Interventional

huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers

NCT07891468
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Richter's Transformation
Interventions
huCART19-IL18-CD428z cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2042
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 12:27 PM EDT
Completed Phase 2 Interventional

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

NCT00434850
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin, Daclizumab or basiliximab, Sirolimus, Tacrolimus, Etanercept
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 30, 2026, 12:27 PM EDT
Terminated No phase listed Observational

B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease

NCT02316691
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 30, 2026, 12:27 PM EDT
Withdrawn Phase 1 Interventional

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT05950113
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Fludeoxyglucose F-18, Immunotherapy, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 30, 2026, 12:27 PM EDT
Completed Phase 2 Interventional

LEA29Y (Belatacept) Emory Edmonton Protocol

NCT00468403
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 30, 2026, 12:27 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Imatinib for Pain in Sickle Cell Anemia

NCT03997903
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Imatinib Mesylate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 25 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Indianapolis, Indiana • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 30, 2026, 12:27 PM EDT